These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
795 related articles for article (PubMed ID: 26889698)
1. Increase in Papillary Thyroid Cancer Incidence Is Accompanied by Changes in the Frequency of the BRAF V600E Mutation: A Single-Institution Study. Kowalska A; Walczyk A; Kowalik A; Pałyga I; Trybek T; Kopczyński J; Kajor M; Chrapek M; Pięciak L; Chłopek M; Góźdź S; Kamiński G Thyroid; 2016 Apr; 26(4):543-51. PubMed ID: 26889698 [TBL] [Abstract][Full Text] [Related]
2. High-sensitivity BRAF mutation analysis: BRAF V600E is acquired early during tumor development but is heterogeneously distributed in a subset of papillary thyroid carcinomas. de Biase D; Cesari V; Visani M; Casadei GP; Cremonini N; Gandolfi G; Sancisi V; Ragazzi M; Pession A; Ciarrocchi A; Tallini G J Clin Endocrinol Metab; 2014 Aug; 99(8):E1530-8. PubMed ID: 24780046 [TBL] [Abstract][Full Text] [Related]
3. The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. Elisei R; Viola D; Torregrossa L; Giannini R; Romei C; Ugolini C; Molinaro E; Agate L; Biagini A; Lupi C; Valerio L; Materazzi G; Miccoli P; Piaggi P; Pinchera A; Vitti P; Basolo F J Clin Endocrinol Metab; 2012 Dec; 97(12):4390-8. PubMed ID: 23066120 [TBL] [Abstract][Full Text] [Related]
4. Molecular Profiling of Papillary Thyroid Carcinoma in Korea with a High Prevalence of BRAF Lee SE; Hwang TS; Choi YL; Kim WY; Han HS; Lim SD; Kim WS; Yoo YB; Kim SK Thyroid; 2017 Jun; 27(6):802-810. PubMed ID: 28293988 [TBL] [Abstract][Full Text] [Related]
5. Classic Architecture with Multicentricity and Local Recurrence, and Absence of TERT Promoter Mutations are Correlates of BRAF (V600E) Harboring Pediatric Papillary Thyroid Carcinomas. Onder S; Ozturk Sari S; Yegen G; Sormaz IC; Yilmaz I; Poyrazoglu S; Sanlı Y; Giles Senyurek Y; Kapran Y; Mete O Endocr Pathol; 2016 Jun; 27(2):153-61. PubMed ID: 26951110 [TBL] [Abstract][Full Text] [Related]
6. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma. Costa AM; Herrero A; Fresno MF; Heymann J; Alvarez JA; Cameselle-Teijeiro J; García-Rostán G Clin Endocrinol (Oxf); 2008 Apr; 68(4):618-34. PubMed ID: 18070147 [TBL] [Abstract][Full Text] [Related]
7. Detection of BRAF c.1799T > A (p.V600E) mutation using residual routine fine-needle aspiration specimens of papillary thyroid carcinoma. Zhao H; Zhang ZH; Zhou B; Xiao T; Pan QJ; Guo HQ Diagn Cytopathol; 2015 Oct; 43(10):786-90. PubMed ID: 26152656 [TBL] [Abstract][Full Text] [Related]
8. Clinical significance of the BRAF V600E mutation in multifocal papillary thyroid carcinoma in Korea. Ahn HY; Chung YJ; Kim BS; Kang KH; Seok JW; Kim HS; Park SJ; Cho BY Surgery; 2014 Apr; 155(4):689-95. PubMed ID: 24612623 [TBL] [Abstract][Full Text] [Related]
9. Immunohistochemistry is highly sensitive and specific for detecting the BRAF V600E mutation in papillary thyroid carcinoma. Sun J; Zhang J; Lu J; Gao J; Lu T; Ren X; Duan H; Liang Z Int J Clin Exp Pathol; 2015; 8(11):15072-8. PubMed ID: 26823846 [TBL] [Abstract][Full Text] [Related]
10. Clinicopathologic correlations of the BRAFV600E mutation, BRAF V600E immunohistochemistry, and BRAF RNA in situ hybridization in papillary thyroid carcinoma. Jung YY; Yoo JH; Park ES; Kim MK; Lee TJ; Cho BY; Chung YJ; Kang KH; Ahn HY; Kim HS Pathol Res Pract; 2015 Feb; 211(2):162-70. PubMed ID: 25468810 [TBL] [Abstract][Full Text] [Related]
11. BRAF overexpression is associated with BRAF V600E mutation in papillary thyroid carcinomas. da Silva RC; de Paula HS; Leal CB; Cunha BC; de Paula EC; Alencar RC; Meneghini AJ; Silva AM; Gontijo AP; Wastowski IJ; Saddi VA Genet Mol Res; 2015 May; 14(2):5065-75. PubMed ID: 26125698 [TBL] [Abstract][Full Text] [Related]
12. Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Fugazzola L; Puxeddu E; Avenia N; Romei C; Cirello V; Cavaliere A; Faviana P; Mannavola D; Moretti S; Rossi S; Sculli M; Bottici V; Beck-Peccoz P; Pacini F; Pinchera A; Santeusanio F; Elisei R Endocr Relat Cancer; 2006 Jun; 13(2):455-64. PubMed ID: 16728573 [TBL] [Abstract][Full Text] [Related]
13. The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma. Pelizzo MR; Dobrinja C; Casal Ide E; Zane M; Lora O; Toniato A; Mian C; Barollo S; Izuzquiza M; Guerrini J; De Manzini N; Merante Boschin I; Rubello D Biomed Pharmacother; 2014 May; 68(4):413-7. PubMed ID: 24721322 [TBL] [Abstract][Full Text] [Related]
14. BRAF(V600E) Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer. Fraser S; Go C; Aniss A; Sidhu S; Delbridge L; Learoyd D; Clifton-Bligh R; Tacon L; Tsang V; Robinson B; Gill AJ; Sywak M World J Surg; 2016 Jul; 40(7):1618-24. PubMed ID: 27138882 [TBL] [Abstract][Full Text] [Related]
15. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study. Daliri M; Abbaszadegan MR; Bahar MM; Arabi A; Yadollahi M; Ghafari A; Taghehchian N; Zakavi SR Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337 [TBL] [Abstract][Full Text] [Related]
16. Genetic alterations of differentiated thyroid carcinoma in iodine-rich and iodine-deficient countries. Vuong HG; Kondo T; Oishi N; Nakazawa T; Mochizuki K; Inoue T; Tahara I; Kasai K; Hirokawa M; Tran TM; Katoh R Cancer Med; 2016 Aug; 5(8):1883-9. PubMed ID: 27264674 [TBL] [Abstract][Full Text] [Related]
17. Concomitant BRAF(V600E) mutation and RET/PTC rearrangement is a frequent occurrence in papillary thyroid carcinoma. Guerra A; Zeppa P; Bifulco M; Vitale M Thyroid; 2014 Feb; 24(2):254-9. PubMed ID: 23806056 [TBL] [Abstract][Full Text] [Related]
18. BRAF V600E does not predict aggressive features of pediatric papillary thyroid carcinoma. Givens DJ; Buchmann LO; Agarwal AM; Grimmer JF; Hunt JP Laryngoscope; 2014 Sep; 124(9):E389-93. PubMed ID: 24604709 [TBL] [Abstract][Full Text] [Related]
19. A high percentage of BRAFV600E alleles in papillary thyroid carcinoma predicts a poorer outcome. Guerra A; Fugazzola L; Marotta V; Cirillo M; Rossi S; Cirello V; Forno I; Moccia T; Budillon A; Vitale M J Clin Endocrinol Metab; 2012 Jul; 97(7):2333-40. PubMed ID: 22508706 [TBL] [Abstract][Full Text] [Related]
20. The BRAF(V600E) mutation influences the short- and medium-term outcomes of classic papillary thyroid cancer, but is not an independent predictor of unfavorable outcome. Russo M; Malandrino P; Nicolosi ML; Manusia M; Marturano I; Trovato MA; Pellegriti G; Frasca F; Vigneri R Thyroid; 2014 Aug; 24(8):1267-74. PubMed ID: 24787545 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]